

1 Comparable seasonal pattern for COVID- 2 19 and Flu-Like Illnesses

3
4 Martijn J. Hoogeveen¹ and Ellen K. Hoogeveen².

5 1. Department Technical Sciences & Environment, Open University, the Netherlands.

6 2. Department of Internal Medicine, Jeroen Bosch Hospital, Den Bosch, the Netherlands.

7 Corresponding author:

8 Martijn J. Hoogeveen

9 martijn.hoogeveen@icecat.com

10

11 **ABSTRACT**

12 **Background:** During the first wave of COVID-19 it was hypothesized that COVID-19 is subject to multi-wave
13 seasonality, similar to Influenza-Like Illnesses since time immemorial. One year into the pandemic, we aimed to
14 test the seasonality hypothesis for COVID-19.

15 **Methods:** We calculated the average annual time-series for Influenza-Like Illnesses based on incidence data
16 from 2016 till 2019 in the Netherlands, and compared these with two COVID-19 time-series during 2020/2021
17 for the Netherlands. We plotted the time-series on a standardized logarithmic infection scale. Finally, we
18 calculated correlation coefficients and used univariate regression analysis to estimate the strength of the
19 association between the time-series of COVID-19 and Influenza-Like Illnesses.

20 **Results:** The time-series for COVID-19 and Influenza-Like Illnesses were strongly and highly significantly
21 correlated. The COVID-19 peaks were all during flu season, and lows were all in the opposing period. Finally,
22 COVID-19 meets the multi-wave characteristics of earlier flu-like pandemics, namely a short first wave at the
23 tail-end of a flu season, and a longer and more intense second wave during the subsequent flu season.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 **Conclusions:** We conclude that seasonal patterns of COVID-19 incidence and Influenza-Like Illnesses incidence
25 are highly similar, in a country in the temperate climate zone, such as the Netherlands. Further, the COVID-19
26 pandemic satisfies the criteria of earlier respiratory pandemics, namely a first wave that is short-lived at the tail-
27 end of flu season, and a second wave that is longer and more severe.

28 This seems to imply that the same factors that are driving the seasonality of Influenza-Like Illnesses are causing
29 COVID-19 seasonality as well, such as solar radiation (UV), temperature, relative humidity, and subsequently
30 seasonal allergens and allergies.

31 **KEYWORDS**

32 COVID-19 incidence, seasonality, Influenza-Like Illnesses, respiratory viruses

33 **HIGHLIGHTS**

- 34 • Time-series analysis shows that COVID-19 and historic of Influenza-Like illnesses have highly similar
35 seasonal patterns in the Netherlands.
- 36 • COVID-19 satisfies the criteria of earlier flu-like pandemics, namely a short cycle at the end of flu
37 season, and a longer, more intense cycle during the subsequent flu season.
- 38 • The implication is that the seasonal factors driving flu season, are also responsible for COVID-19
39 seasonality.
- 40 • We developed and applied a new method to determine seasonality, encompassing comparative time-
41 series analysis, a standardized logarithmic infection scale, and qualitative seasonality criteria.

42

43 **1. INTRODUCTION**

44 During the first wave of COVID-19 it was hypothesized that COVID-19 is subject to multi-wave seasonality [1,
45 2], comparable to other respiratory viral infections and pandemics since time immemorial [3, 4]. It is observed
46 that the COVID-19 community outbreaks have a similar pattern as other seasonal respiratory viruses [5, 6, 7].
47 Already during the first COVID-19 cycle the data suggested seasonality, comparable to the seasonality of
48 Influenza-Like Illnesses (ILI), although the time-series were typically too short for definitive conclusions [8].
49 Currently, we are one year into the COVID-19 pandemic, and we can witness in the temperate climate zone in

50 the Northern Hemisphere, a second wave that appears to rise and peak during the boundaries of a typical flu
51 season, as the first cycle before.

52 Until now, it is not yet confirmed that COVID-19 behaves as seasonal as ILI. Therefore, we aim to test our
53 hypothesis that COVID-19 has a similar seasonal pattern as ILI in a country in the temperate climate zone as the
54 Netherlands. To test our hypothesis, we performed time-series analysis to compare the COVID-19 cycles with
55 the multi-wave seasonality patterns of flu-like illnesses. In addition, we analyzed to what degree the COVID-19
56 pandemic fulfills the qualitative characteristics of earlier flu-like pandemics and seasonality as mentioned by Fox
57 et al. Particularly, a short first wave at the tail end of a flu season, and a more severe second wave during the
58 following flu season. We further expect peaks to occur within the seasonal boundaries between week 33 (± 2
59 weeks) and week 10 (± 5 weeks), and the nadir in the opposing period which coincides with the allergy season
60 [8, 9].

61 The main objective of this study is to provide a predictive model for subsequent COVID-19 seasonal cycles.

62

63 **2. METHODS**

64 **2.1 Data**

65 *Incidence of Influenza-Like Illnesses*

66 We used data from the Dutch State Institute for Public Health (RIVM) gathered by the Dutch institute for
67 research of the health care (Nivel) about weekly flu-like incidence (WHO code “ILI” - Influenza-Like Illnesses).
68 ILI is defined by the WHO as a combination of a measured fever of $\geq 38^{\circ}\text{C}$, and a cough, with an onset within
69 the last 10 days. The Dutch ILI reports are gathered from primary medical care. Primary medical care is the first-
70 line healthcare provided by general practitioners to their registered patients as typical in the Netherlands, with its
71 current population of 17.4 million. The reports are confirmed by a positive RIVM laboratory test for ILI [10].

72 The flu-like incidence metric is a weekly average based on a representative group of 40 primary care units. It is
73 calculated using the number of influenza-like reports per primary care unit divided by the number of patients
74 registered at that unit. This is then averaged for all primary care units in the Netherlands, extrapolated to the
75 entire population, and reported as the ‘ILI incidence per 100,000 citizens in the Netherlands’. The datasets run
76 from week 1 of 2016 up to week 52 of 2019 to preclude the COVID-19 pandemic and avoid the impact of

77 lockdowns and other COVID-19 related restrictions on ILI in the 2020/2021 season. We used these data to
78 calculate the average ILI incidence per week ($n = 52$) as our baseline times series.

79 *COVID-19 incidence*

80 To calculate the COVID-19 incidence, we used the RIVM data set which reports the daily COVID-19 incidence
81 per municipality [11]. The incidence per municipality is based on positive COVID-19 tests that are reported via
82 the local municipality health services (Gemeentelijke Gezondheidsdienst; GGD), that are under the control of the
83 RIVM. We aggregated the crude number into a weekly COVID-19 incidence for the Netherlands per 100,000
84 citizens, to create a metric on the same scale as the standard ILI metric. We calculated the values from week 13,
85 2020, the peak of the short first COVID-19 cycle in the Netherlands, till week 5, 2021 ($n = 45$). We assume that
86 the cycles themselves are sufficiently representative for time-series analysis, even though the COVID-19
87 incidence during the first cycle is most likely underestimated compared to incidence during the second cycle, due
88 to test bias. With test bias, we mean that both the method of testing and the test capacity, altered during the
89 development of the COVID-19 pandemic. Especially, at the start of the pandemic, there was a shortage of test
90 capacity in the Netherlands. The capacity shortage had considerably improved since the end of March, i.e., week
91 13 of 2020, but only in the first months of 2021 reached sufficient levels.

92 Therefore, as a sensitivity analysis, we used a second dataset from RIVM, which is based on data from the Dutch
93 national intensive care evaluation foundation [12]. Based on hospital admissions, the RIVM estimated the
94 COVID-19 incidence in the Netherlands, assuming a delay of at least 7 days between the COVID-19 infection
95 and hospital admission. This dataset provides the average COVID-19 incidence per day with a 95% confidence
96 interval (95% CI). Again, we calculated the average weekly COVID-19 incidence for the Netherlands per
97 100,000 citizens, to create a metric on the same scale as the standard ILI metric.

98

99 **2.2 Statistical analysis**

100 Variables are presented with their means (M) and standard deviations (SD). We calculated correlation
101 coefficients to test the hypotheses and to assess the strength and direction of relationships.

102

103 Because the time-series were nonlinear and somewhat skewed, we used the \log_{10} transformation before applying
104 linear regression and calculating correlation coefficients, which requires a normal distribution. After the \log_{10}
105 transformation, we multiplied the data with factor 2 to create an intuitive scale from 0 to 10 for ILI and COVID-

106 19, which is comparable to the 1 to 12 logarithmic Richter scale for earthquakes [13]. The logarithmic scale we
107 elaborated is rational and plots exponential characteristics on a linear infections scale [14]. We added descriptive
108 labels to each scale as an aid for qualitative interpretation in intuitive, layman terms (see Table 1). Other
109 advantages are that it makes a comparison between different epidemics or pandemics, and thus external
110 validation, easier. Finally, it enlarges the critical early stages of an epidemic, and it reduces the extreme peaks
111 and resulting test bias because of test capacity overloads.

112

113 Linear regression (F-test) on the ILI and COVID-19 time-series is performed as a sensitivity analysis and used
114 *descriptively* to determine the strength of the relationship between the COVID-19 and ILI time-series. More in
115 detail to determine the equation using estimates and intercept values, probability, significance level, F-value, and
116 the Multiple R squared correlation to understand the predictive power of the respective relation. Standard
117 deviations and errors and degrees of freedom (DF) were used as input for calculating the 95% probability
118 interval.

119 We have reported the results in APA style, adapted to journal requirements.

120 Correlations are calculated manually in Excel, and for linear regression Graphpad 2021 is used (which we
121 benchmarked on R version 3.5).

122

123 **3. RESULTS**

124 **3.1 Data analysis**

125 The means and standard deviations of the dataset are summarized in Table 2.

126 Figure 1 shows a short first COVID-19 wave at the tail end of the 2019/2020 flu season, and a more severe
127 second wave during the 2020/2021 flu season in terms of total incidence. The peaks are all within the seasonal
128 boundaries between week 33 (± 2 weeks) and week 10 (± 5 weeks), and the nadirs in the opposing period. The
129 hospitalizations-based estimates for COVID-19 incidence provide likely a more realistic picture of especially,
130 the first wave, given test bias. However, on a logarithmic scale, the first COVID-19 wave appears more visually
131 comparable in both time-series.

132 On our logarithmic infection scale (Fig. 2), the estimated COVID-19 incidence tops around 6 (severe epidemic
133 level), and the nadir bottoms out around 3 (severe outbreak level). Interestingly, on this scale, it becomes visible
134 that COVID-19 incidence starts to rise slightly earlier than what is usual for ILI (week 33 ± 2 weeks).

135

136 **3.2 Statistical outcomes**

137 The COVID-19 time-series strongly and highly significantly correlates with the ILI time-series $r(45) = 0.75$ ($p <$
138 0.00001). The hospitalizations-based, COVID-19 time-series, providing estimates that control for test bias,
139 correlated even somewhat stronger, ($r(45) = 0.798$, $p < 0.00001$), and as significantly (Fig. 3). The correlations
140 (95% CI) of the estimated COVID-19 incidence time-series are almost equal, respectively $r(45) = 0.788$, $p <$
141 0.00001 and $r(45) = 0.803$, $p < 0.00001$. Therefore, we conclude that the COVID-19 time-series have a similar
142 wave pattern to the ILI time-series, which have long been established as being seasonal. Furthermore, the
143 COVID-19 peaks, similar to ILI peaks, all occur during flu season, i.e., between week $33 (\pm 2$ weeks) and week
144 $10 (\pm 5$ weeks). In addition, the COVID-19 nadirs, similar to ILI nadirs, occur all in the opposing allergy season.

145 As a second sensitivity analysis, we performed univariate regression analyses between both the COVID-19 time-
146 series, and the average ILI time-series. The outcomes were again highly significant: respectively $F(1, 43) =$
147 61.45 , $p < 0.0001$, and $F(1, 43) = 81.18$, $p < 0.0001$ and the correlations (r^2) are moderate to strong (see Table
148 3).

149

150 **4. DISCUSSION**

151 Given the strong, and highly significant, correlations between the ILI and COVID-19 time-series, we conclude
152 that COVID-19 incidence follows a seasonal pattern that is similar to ILI incidence in a country in the temperate
153 climate zone, such as the Netherlands. Moreover, the COVID-19 peaks are all during flu season, and lows are all
154 in the opposing period as expected. Furthermore, the COVID-19 time-series is in accordance with the two
155 characteristics of earlier pandemics [4], namely a short first wave at the tail-end of a flu season, and a longer and
156 more intense second wave during the subsequent flu season. This implies that the subsequent endings and starts
157 of each following wave are more or less predictable. If the history of pandemics is followed, the third COVID-19
158 wave would be less severe than the second one. Though nowadays vaccination will be a more important factor in
159 determining the amplitude of the subsequent waves.

160 Interestingly, all over Europe, the COVID-19 cycles were all more or less in sync with the Dutch COVID-19
161 cycle [15], and thus ILI seasonality, independent of the start of the first cycle, the severity of lockdown measures
162 taken, and given that herd immunity is not yet reached. The seasonality pattern of COVID-19 appears to be
163 influenced though not caused by social distancing and lockdown measures as these measures were mainly anti-
164 cyclical and following the trend. They were increasingly applied to flatten the curve after COVID-19 incidence
165 increases, gradually lifted after the sharper than expected COVID-19 downcycles in Spring and Summer, and
166 only re-applied after the second wave seriously kicked in, during Autumn and Winter. It is beyond our research
167 to quantify the considerable impact of lockdown and social distancing measures, although it might explain that
168 COVID-19 incidence on the logarithmic scale (see Fig. 2) starts to rise slightly earlier than what is usual for ILI
169 (week 33 ± 2 weeks) as social distancing and lockdown measures were increasingly relaxed and ignored in this
170 period.

171 What environmental factors have caused COVID-19 seasonality? We have analyzed before that the likely
172 inhibiting factor causing ILI seasonality, before or during COVID-19, are seasonal allergens (i.e. pollens) and
173 seasonal allergies [8, 9], given that meteorological factors alone are not sufficient to explain the seasonality of
174 ILI [16] or COVID-19 [17]. We used data from a pollen station in Helmond, the Netherlands (latitude 51.48167,
175 longitude 5.66111). On the other hand, we identified solar radiation (UV) as an ILI/COVID-19 co-inhibitor, and
176 it is well-established that dry, warm, and sunny weather stimulates the maturation and dispersion of pollens.

177 The inverse seasonality of seasonal allergens and ILI including COVID-19 is independently confirmed by a
178 recent Chicago (latitude 41.85003, longitude -87.65005) study that covered not only pollens but also mold
179 spores [18]. These findings seemingly contradict an early international study of pollen and COVID-19 [19],
180 which suffers from the same issues as many other early environmental COVID-19 studies: both sub-seasonal
181 bias and COVID-19 test bias. Sub-seasonal bias, means here that a too limited time-series sample is used,
182 namely from January till the beginning of April 2020, which coincides with only a small part of the early
183 upswing in COVID-19 incidence in most countries, and mainly the upswing of allergens in the northern
184 hemisphere. Further, the assumed lag of precisely 4 days seems to be problematic as people typically do not get
185 immediately tested when they show the first COVID-19 symptoms. Additionally, conflicting local outcomes
186 were selectively removed from the study. And, finally, in this short time window used it might have been better
187 to correlate with a sound R_0 estimate, correcting for test bias, than only the raw incidence figures, to be able to
188 discern deceleration/acceleration effects during the upswing.

189 We think that studies that are more geographically focused, and work with longer time-series, are in the current

190 phase more meaningful for analyzing the pollen effect on COVID-19 incidence while controlling for deviations
191 in other local circumstances. Therefore, we would expect that, ceteris paribus, the results of our COVID-19 and
192 ILI pattern comparison in this study, implies that a 12-month time-series analysis of the R_0 of COVID-19 and
193 pollen concentrations would falsify the outcomes of this international study, at least for the Netherlands.

194 Although the allergenic role of pollen is widely known [20, 21, 22], its role in immuno-activation [23] is
195 highlighted only recently. Owing to extensive COVID-19 research, pathophysiological explanations have been
196 established upon the observation that allergic diseases are associated with lower rates of COVID-19
197 hospitalizations [24, 25]. An explanation is provided by Jackson et al. [26], who proved that allergic sensitization
198 and allergen natural exposure are inversely related to membrane-bound angiotensin-converting enzyme 2 (ACE-
199 2) expression, whereby it is known that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses the
200 ACE-2 receptor to gain cell entry, leading to COVID-19 [27]. Additionally, it is hypothesized that seasonal
201 allergens, especially pollen and mold spores, compete with flu-like viruses for access to another receptor, the
202 Toll-Like Receptor 4 (TLR4) [18], in an attempt to explain the inverse seasonality of seasonal allergens and flu-
203 like illnesses, both for people with and without allergic diseases.

204 Another explanation is based on the higher eosinophil count in children with allergic diseases than COVID-19
205 patients [28], whereby eosinophils are known to clear viral load, and contribute to the recovery from viral
206 infections, supposedly including COVID-19 [29].

207 Furthermore, histamine and IgE serum levels are elevated in allergic rhinitis and other atopy patients which
208 downplay other anti-viral responses (plasmacytoid dendritic cells and interferon- α) but might thus prevent the
209 cytokine storm and hyper-inflammation that typically mark severe outcomes of respiratory diseases, including
210 COVID-19 [30] and influenza. And, it is discussed that homologies between SARS-CoV-2 and allergen proteins,
211 especially from the spores of molds (*Aspergillus fumigatus*) and the pollen of grasses (*Phleum pratense*) may
212 direct T cell-mediated heterologous immune responses [31] which might help explain the protective effect of
213 allergies against COVID-19 hospitalization as well.

214 Finally, it is well-established that pollens have anti-viral phytochemicals [32], which is also the case for mold
215 spores [33]. Although the nature of the bioaerosol interaction with COVID-19 viruses is not well investigated yet
216 it can be imagined that pollens and spores might compete with viral bioaerosol in the environment.

217 *Methodological concerns*

218 Test bias, especially for new viruses such as COVID-19, is a major methodological challenge. The approach to
219 use more reliable metrics like the number of hospitalizations to generate an alternative incidence metric appears
220 to be a good method to control for test bias. We could observe that the test bias slightly reduced the strength of
221 correlations, which in our case did not affect the conclusions. During 2020-2021, the test capacity was scaled up
222 significantly and sufficiently, which reduced the test bias concern over time.

223 Another sound approach used seems to be excess mortality estimates. In this study, we decided not to use the
224 latter, as there are other known factors than seasonal viruses that cause excess mortality, such as the heatwave
225 during the Summer of 2020. Thus, using excess mortality would just introduce a measurement validity concern.
226

227 **5. CONCLUSION**

228 The COVID-19 pandemic in the Netherlands is till now as seasonal as flu-like illnesses given the highly
229 significant and strong correlations between both time-series. But, also given that COVID-19 waves till now rise
230 between the temporal boundaries (week 10 \pm 5 weeks and week 33 \pm 2 weeks) of the typical flu-like season in
231 The Netherlands, and go down in the opposing periods. Further, the COVID-19 pandemic satisfies the
232 qualitative criteria of earlier respiratory pandemics since 1889: the first wave is short-lived at the tail-end of flu
233 season, the second wave is longer and more severe, peaks fall within the boundaries of flu-like season, and the
234 lows are during the boundaries of the opposing season.

235 This logically seems to imply that, *ceteris paribus*, the same factors that are driving the seasonality of Influenza-
236 Like Illnesses are causing COVID-19 seasonality, such as solar radiation (UV), temperature, relative humidity,
237 and subsequently seasonal allergens and allergies.
238

239 **REFERENCES**

- 240 1. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of
241 SARS-CoV-2 through the post-pandemic period. *Science*. **2020**;368(6493): 860-868,
242 <https://doi.org/10.1126/science.abb5793>.
- 243 2. Grech V, Cuschieri S, Gauci C. COVID-19: The possible seasonal shape of things to come. *Early Hum*
244 *Dev*. **2020** Nov 12: 105262, <https://doi.org/10.1016/j.earlhumdev.2020.105262>.
- 245 3. Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of Respiratory Viral Infections. *Annual Review*
246 *of Virology*. **2020**;7:1, <https://doi.org/10.1146/annurev-virology-012420-022445>.

- 247 4. Fox SJ, Miller JC, Meyers LA. Seasonality in risk of pandemic influenza emergence. *PLoS Comput*
248 *Biol* **2017**; 13(10): e1005749, <https://doi.org/10.1371/journal.pcbi.1005749>.
- 249 5. Sajadi MM, Habibzadeh P, Vintzileos A, Shokouhi S, Miralles-Wilhelm F, Amoroso A. Temperature,
250 Humidity and Latitude Analysis to Predict Potential Spread and Seasonality for COVID-19. **2020**
251 March 5, <https://doi.org/10.2139/ssrn.3550308>.
- 252 6. Poole L. Seasonal Influences On The Spread Of SARS-CoV-2 (COVID19), Causality, and
253 Forecastability (3-15-2020) (March 15, 2020), <https://doi.org/10.2139/ssrn.3554746>.
- 254 7. Burra P, Soto-Díaz K, Chalen I, Gonzalez-Ricon RJ, Istanto D, Caetano-Anollés G. Temperature and
255 Latitude Correlate with SARS-CoV-2 Epidemiological Variables but not with Genomic Change
256 Worldwide. *Evolutionary Bioinformatics*. **2021** January, <https://doi.org/10.1177/1176934321989695>.
- 257 8. Hoogeveen MJ, Van Gorp ECM, Hoogeveen EK. Can pollen explain the seasonality of flu-like illnesses
258 in the Netherlands? *Sci Total Environ*. **2021** Feb 10;755(Pt 2):143182,
259 <https://doi.org/10.1016/j.scitotenv.2020.143182>.
- 260 9. Hoogeveen MJ. Pollen likely seasonal factor in inhibiting flu-like epidemics. A Dutch study into the
261 inverse relation between pollen counts, hay fever and flu-like incidence 2016–2019, *Sci Total Environ*.
262 **2020** July 20; 727:138543, <https://doi.org/10.1016/j.scitotenv.2020.138543>.
- 263 10. RIVM/ILI data. Griep en grieprik. Feiten en cijfers. [https://www.rivm.nl/griep-grieprik/feiten-en-](https://www.rivm.nl/griep-grieprik/feiten-en-cijfers)
264 [cijfers](https://www.rivm.nl/griep-grieprik/feiten-en-cijfers). Accessed May 15, **2020**.
- 265 11. [dataset] RIVM/GGD. COVID-19 incidence per Dutch municipality by GGDs.
266 [https://data.rivm.nl/geonetwork/srv/dut/catalog.search#/metadata/1c0fcd57-1102-4620-9cfa-](https://data.rivm.nl/geonetwork/srv/dut/catalog.search#/metadata/1c0fcd57-1102-4620-9cfa-441e93ea5604)
267 [441e93ea5604](https://data.rivm.nl/geonetwork/srv/dut/catalog.search#/metadata/1c0fcd57-1102-4620-9cfa-441e93ea5604). Accessed February 14, **2021**.
- 268 12. [dataset] RIVM/NICE. Estimated prevalence COVID-19 on the basis of a 95% confidence interval.
269 https://data.rivm.nl/covid-19/COVID-19_prevalentie.json. Accessed February 14, **2021**.
- 270 13. Boore DM. The Richter scale: its development and use for determining earthquake source parameters,
271 *Tectonophysics*. **1989**;166(1–3): 1-14, [https://doi.org/10.1016/0040-1951\(89\)90200-X](https://doi.org/10.1016/0040-1951(89)90200-X).
- 272 14. Steffen R. Travel vaccine preventable diseases—updated logarithmic scale with monthly incidence
273 rates, *Journal of Travel Medicine*. 2018;25(1): tay046, <https://doi.org/10.1093/jtm/tay046>.
- 274 15. Reuters COVID-19 tracker Europe [https://graphics.reuters.com/world-coronavirus-tracker-and-](https://graphics.reuters.com/world-coronavirus-tracker-and-maps/regions/europe/)
275 [maps/regions/europe/](https://graphics.reuters.com/world-coronavirus-tracker-and-maps/regions/europe/). Accessed on February 28, 2021.

- 276 16. Tamerius J, Nelson MI, Zhou SZ, Viboud C, Miller MA, Alonso WJ. (2011). Global influenza
277 seasonality: reconciling patterns across temperate and tropical regions. *Environmental health*
278 *perspectives*, 119(4), 439–445, <https://doi.org/10.1289/ehp.1002383>.
- 279 17. Kerr GH, Badr HS, Gardner LM, Perez-Saez J, Zaitchik BF. Associations between meteorology and
280 COVID-19 in early studies: Inconsistencies, uncertainties, and recommendations. *One Health*.
281 **2021**;12:100225, <https://doi.org/10.1016/j.onehlt.2021.100225>.
- 282 18. Shah RB, Shah RD, Retzinger DG, Retzinger AC, Retzinger DA, Retzinger GS. Confirmation of an
283 Inverse Relationship between Bioaerosol Count and Influenza-like Illnesses, Including COVID-19. On
284 the Contribution of Mold Spores. *MedrXiv* 21251322 [preprint]. Feb 16, 2021 [cited March 1, 2021].
285 Available on: <https://doi.org/10.1101/2021.02.07.21251322>.
- 286 19. Damialis A, Gilles S, Sofiev M, Sofieva V, Kolek F, Bayr D, Plaza MP, Leier-Wirtz V, Kaschuba S,
287 Ziska LH, Bielory L, Makra L, Del Mar Trigo M, COVID-19/POLLEN study group, Claudia Traidl-
288 Hoffmann. Higher airborne pollen concentrations correlated with increased SARS-CoV-2 infection
289 rates, as evidenced from 31 countries across the globe. *Proceedings of the National Academy of*
290 *Sciences*. 2021 Mar;118(12): e2019034118, <https://doi.org/10.1073/pnas.2019034118>.
- 291 20. Klemens C, Rasp G, Jund F, Hilgert E, Devens C, Pfrogner E, Kramer MF. Mediators and cytokines in
292 allergic and viral-triggered rhinitis. *Allergy & Asthma Proceedings*. **2007**;28(4): 434-441.
- 293 21. Rosenwasser LJ. Current Understanding of the Pathophysiology of Allergic Rhinitis. *Immunology and*
294 *Allergy Clinics*. 2011;31(3): 433-439.
- 295 22. Howarth PH. Allergic rhinitis: not purely a histamine-related disease. *European Journal of Allergy and*
296 *Clinical Immunology* **2000**;55(s64): 7-16.
- 297 23. Brandelius A, Andersson M, Uller L. Topical dsRNA challenges may induce overexpression of airway
298 antiviral cytokines in symptomatic allergic disease. A pilot in vivo study in nasal airways. *Respiratory*
299 *Medicine*. **2020**; 108(12): 1816-1819, <https://doi.org/10.1016/j.rmed.2014.10.010>.
- 300 24. Larsson SC, Gill D. Genetic predisposition to allergic diseases is inversely associated with risk of
301 COVID-19. *Allergy* **2021 Dec 31**, <https://doi.org/10.1111/all.14728>.
- 302 25. Keswani A, Dhana K, Rosenthal JA, Moore D, Mahdavinia M. *Ann Allergy Asthma Immunol*.
303 **2020**;125(4): 479–481, <https://doi.org/10.1016/j.anai.2020.07.012>.

- 304 26. Jackson DJ, Busse WW, Bacharier LB, et al. Association of respiratory allergy, asthma, and expression
305 of the SARS-CoV-2 receptor, ACE2. *J Allergy Clin Immunol* **2020**;
306 <https://doi.org/10.1016/j.jaci.2020.04.009>.
- 307 27. Wan Y et al. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on
308 Decade-Long Structural Studies of SARS Coronavirus. *J. Virol.* **2020**. [Epub ahead of print].
309 <https://jvi.asm.org/content/94/7/e00127-20.long>
- 310 28. Licari A, Votto M, Brambilla I, Castagnoli R, Piccotti E, Olcese R., Tosca MA, Ciprandi G, Marseglia
311 GL. Allergy and asthma in children and adolescents during the COVID outbreak: What we know and
312 how we could prevent allergy and asthma flares. *Allergy.* **2020** Sep;75(9):2402-2405,
313 <https://doi.org/10.1111/all.14369>.
- 314 29. Lindsley AW, Schwartz JT, Rothenberg ME. Eosinophil responses during COVID-19 infections and
315 coronavirus vaccination. *J Allergy Clin Immunol.* **2020** Jul;146(1):1-7,
316 <https://doi.org/10.1016/j.jaci.2020.04.021>.
- 317 30. Carli G, Cecchi L, Stebbing J, Parronchi P, Farsi A. Is asthma protective against COVID-19? *Allergy*
318 **2020**;76(3): 866-868, <https://doi.org/10.1111/all.14426>.
- 319 31. Balz K, Kaushik A, Chen M et al. Homologies between SARS-CoV-2 and allergen proteins may direct
320 T cell-mediated heterologous immune responses. *Sci Rep* 11, 4792 (2021),
321 <https://doi.org/10.1038/s41598-021-84320-8>.
- 322 32. Kapoor R, Sharma B, Kanwar SS. Antiviral Phytochemicals: An Overview. *Biochem Physiol.*
323 **2017**;6:220, <https://doi.org/10.4172/2168-9652.1000220>.
- 324 33. Linnakoski R, Reshamwala D, Veteli P, Cortina-Escribano M, Vanhanen H, Marjomäki V. Antiviral
325 agents from fungi: diversity, mechanisms and potential applications. *Front. Microbiol.* 2018; 9: 2325,
326 <https://doi.org/10.3389/fmicb.2018.02325>.

327

328 FIGURES AND TABLES

329

Table 1: Logarithmic Infection Scale

2*LOG₁₀(Incidence/100K)	Incidence	Incidence (% of	Description
	(/100K citizens)	population	
		infected)	

0	1	0.001%	Isolated incidents
1	3	0.003%	Mild outbreak
2	10	0.01%	Moderate outbreak
3	30	0.03%	Severe outbreak
3.5	58	0.06%	Epidemic threshold (example)
4	100	0.1%	Mild Epidemic
5	300	0.3%	Moderate epidemic
6	1000	1%	Severe epidemic
7	3000	3%	Very severe epidemic
8	10000	10%	Public health catastrophe
9	30000	30%	Severe public health catastrophe
10	100000	100%	Total public health catastrophe

330 *Table 1: Logarithmic scale [1, 10] of Influenza-Like Illnesses or COVID-19 (or other) incidence because of the*
331 *exponential nature of epidemics, with proposed qualitative descriptions for convenience.*

332 **Table 2: overview means (M) and standard deviations (SDs)**


Variable	2*Log ₁₀ transformed			
	Mean	SD	Mean	SD
Average incidence ILI/100K 2016 till 2019	46	36	3.07	0.69
COVID-19 incidence/100K	126	141	3.34	1.43
COVID-19 incidence/100K estimate based on hospitalizations (average)	415	337	4.69	1.17
COVID-19 incidence/100K estimate based on hospitalizations (lower 95% CI)	300	247	4.38	1.22
COVID-19 incidence/100K estimate based on hospitalizations (upper 95% CI)	531	426	4.93	1.14

333 *Table 2: Overview of means (M) and standard deviations (SD) per variable in the ILI (Influenza-Like Illnesses)*
334 *and COVID-19 datasets, including 2*Log₁₀ transformed data.*

335

336

Figure 1.




337

338 *Fig. 1. Historical ILI (Influenza-Like Illnesses) incidence (2016 till 2019) versus COVID-19 incidence per 100K*
339 *citizens during the 2020/2021 season. Peaks are all during flu season, and lows during the opposite season. The*
340 *shaded periods are the typical period in which seasonal switching occurs.*

341

Figure 2.

342




343

344 *Fig. 2. Historical ILI (Influenza-Like Illnesses) incidence (2016 till 2019) versus COVID-19 incidence per 100K*
345 *citizens (2020/2021) on the 1 to 10 logarithmic scale. This figure visualizes the similarity of the COVID-19 time-*
346 *series based on hospitalizations with the historic ILI time-series. The shaded areas are the typical seasonal*
347 *switching periods.*

348

349

Figure 3.



350

351 *Fig. 3. Scatter diagram showing the relation between the estimated COVID-19 incidence/100K citizens and the*
 352 *seasonal, average incidence of Influenza-Like Illnesses (ILI)/100K citizens in the Netherlands of the preceding 4*
 353 *years.*

354

Table 3: outcomes linear regression

355

356

357

2*LOG₁₀(ILI/100K)	Estimate	CI 95%	Intercept	R²	F-stat on DF	P<
2*LOG₁₀(COVID-19 incidence/100K)	1.81	1.34 to 2.28	1.95	0.59	61.45 (1, 43)	0.0001

2*LOG₁₀(COVID-19							
incidence/100K) estimate	1.54	1.20 to 1.89	0.19	0.65	81.18 (1, 43)	0.0001	
based on hospitalizations							

358

359 *Table 3: Univariate regression analyses of the average Influenza-Like Illnesses (ILI) incidence/100K citizens on*
360 *both time-series for COVID-19 incidence/100K citizens, whereby each time-series is 2*LOG₁₀ transformed to*
361 *compensate for non-linearity, and thus plotted on a 1 to 10 rational scale.*

362

363

364 **FOOTNOTES PAGE**

365 **Martijn Hoogeveen:** Conceptualization, Methodology, Data Curation, Formal Analysis, Writing,
366 Investigation, Visualization, Resources

367 **Ellen Hoogeveen:** Methodology, Reviewing and Editing, Resources

368 **Funding**

369 This research did not receive any specific grant from funding agencies in the public, commercial, or
370 not-for-profit sectors.

371 **Declarations of interest**

372 None.

373 **Data statement**

374 The links to the COVID-19 datasets are provided in the reference list and a reference to the source of
375 Influenza-Like Illnesses. Upon request, the data used for this manuscript is available for inspection,
376 but for other purposes we kindly refer to the respective copyright-holder(s).

377 **Corresponding author**

378 Martijn Hoogeveen, PhD, affiliate professor

379 Icecat/Division of Technology & Environment

380 Open Universiteit Nederland

381 Valkenburgerweg 177

382 6419 AT Heerlen


383 the Netherlands

384 Tel: +31 (6) 54256476

385 Email: martijn.hoogeveen@icecat.com.

386 **MATERIALS**


387 **Linear Regression**



388

Best-fit values	
Slope	1.810 ± 0.2309
Y-intercept	-1.946 ± 0.6886
X-intercept	1.075
1/Slope	0.5524
95% Confidence Intervals	
Slope	1.344 to 2.276
Y-intercept	-3.335 to -0.5566
X-intercept	0.4106 to 1.477
Goodness of Fit	
R square	0.5883
Sy.x	0.9350
Is slope significantly non-zero?	
F	61.45
DFn,DFd	1,43
P Value	< 0.0001
Deviation from horizontal?	Significant
Data	
Number of XY pairs	45
Equation	$Y = 1.810 * X - 1.946$

389



390

Best-fit values	
Slope	1.544 ± 0.1714
Y-intercept	0.1862 ± 0.5111
X-intercept	-0.1206
1/Slope	0.6475
95% Confidence Intervals	
Slope	1.198 to 1.890
Y-intercept	-0.8450 to 1.217
X-intercept	-1.011 to 0.4491
Goodness of Fit	
R square	0.6537
Sy.x	0.6939
Is slope significantly non-zero?	
F	81.18
DFn,DFd	1,43
P Value	< 0.0001
Deviation from horizontal?	Significant
Data	
Number of XY pairs	45
Equation	Y = 1.544*X + 0.1862